# Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

> **NCT05431764** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 38 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab, gemcitabin, cisplatin
- **RADIATION:** Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy

## Key facts

- **NCT ID:** NCT05431764
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2025-06-20
- **Final completion:** 2026-06-20
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2022-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431764, "Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05431764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*